A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

Trial Profile

A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 May 2017

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Lewy body disease
  • Focus Registrational; Therapeutic Use
  • Acronyms HEADWAY-DLB
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 12 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 09 Jan 2017 According to an Axovant Sciences media release, results from the study are expected in the fourth quarter of 2017.
    • 23 Feb 2016 According to Axovant media release, data from this trial will be presented at the Cowen and Company 36th Annual Health Care Conference on March 8.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top